The endocannabinoid system: Overview of an emerging multi-faceted therapeutic target

Dipanjan Chanda, Dietbert Neumann, Jan F. C. Glatz*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

281 Downloads (Pure)

Abstract

The endocannabinoids anandamide (AEA) and 2-arachidonoylglyerol (2-AG) are endogenous lipid mediators that exert protective roles in pathophysiological conditions, including cardiovascular diseases. In this brief review, we provide a conceptual framework linking endocannabinoid signaling to the control of the cellular and molecular hallmarks, and categorize the key components of endocannabinoid signaling that may serve as targets for novel therapeutics. The emerging picture not only reinforces endocannabinoids as potent regulators of cellular metabolism but also reveals that endocannabinoid signaling is mechanistically more complex and diverse than originally thought.

Original languageEnglish
Pages (from-to)51-56
Number of pages6
JournalProstaglandins Leukotrienes and Essential Fatty Acids
Volume140
DOIs
Publication statusPublished - Jan 2019

Keywords

  • 2-arachidonoylglyerol
  • Anandamide
  • Insulin resistance
  • Ccardiovascular disease
  • CB2 CANNABINOID RECEPTORS
  • PHARMACOLOGICAL STRATEGIES
  • SPECIES-DIFFERENCES
  • RISK-FACTORS
  • RIMONABANT
  • PAIN
  • IDENTIFICATION
  • HYPOTHALAMUS
  • MODULATION
  • OVERWEIGHT

Cite this